# Report 5: CDx Company Landscape

## 1. Executive Summary
This report summarizes the major Companion Diagnostic (CDx) manufacturers identified in the OncoKB FDA-approved dataset.
It maps each company's devices to the specific Drug-Indication pairs they are approved to identify.

---

## 2. Foundation Medicine, Inc.
**Dominance:** The clear market leader for NGS-based CDx, covering the widest range of solid tumors and therapies.

### Device: FoundationOne CDx (F1CDx)
*   **Solid Tumors (General):**
    *   **Larotrectinib / Entrectinib:** NTRK1/2/3 Fusions
    *   **Pembrolizumab:** MSI-High (MSI-H), TMB-High (TMB-H)
    *   **Selpercatinib:** RET Fusions
*   **Non-Small Cell Lung Cancer (NSCLC):**
    *   **Osimertinib:** EGFR Exon 19 del, L858R, T790M
    *   **Alectinib / Crizotinib / Ceritinib:** ALK Fusions
    *   **Capmatinib:** MET Exon 14 skipping
    *   **Dabrafenib + Trametinib:** BRAF V600E
*   **Prostate Cancer:**
    *   **Olaparib:** BRCA1/2, ATM, CDK12, CHEK1/2, PALB2, and other HRR genes.
*   **Breast Cancer:**
    *   **Alpelisib:** PIK3CA Mutations
    *   **Trastuzumab:** ERBB2 (HER2) Amplification
*   **Ovarian Cancer:**
    *   **Olaparib:** BRCA1/2
*   **Melanoma:**
    *   **Dabrafenib + Trametinib:** BRAF V600E/K

### Device: FoundationOne Liquid CDx (Liquid Biopsy)
Used when tissue is unavailable, covering a subset of the tissue assay's indications.
*   **NSCLC:** EGFR (Exon 19/20/L858R/T790M), ALK, MET, ROS1, BRAF
*   **Prostate:** BRCA1/2, ATM (Olaparib, Rucaparib)
*   **Breast:** PIK3CA (Alpelisib)
*   **Colorectal:** BRAF V600E (Encorafenib)

---

## 3. Roche Molecular Systems, Inc. / Life Technologies
**Focus:** Specific single-gene PCR assays and the OncoKB Dx NGS panel.

### Device: cobas EGFR Mutation Test v2 (Roche)
*   **NSCLC:** EGFR Exon 19 del, L858R, T790M (Osimertinib, Erlotinib, Gefitinib)

### Device: cobas KRAS Mutation Test (Roche)
*   **Colorectal Cancer:** KRAS Wildtype confirmation (Cetuximab, Panitumumab)

### Device: cobas 4800 BRAF V600 Mutation Test (Roche)
*   **Melanoma:** BRAF V600E (Vemurafenib + Cobimetinib)

### Device: OncoKB Dx Target Test (Life Technologies/Thermo Fisher)
*   **NSCLC:** BRAF V600E, EGFR Exon 20 ins, RET Fusions, ROS1 Fusions
*   **Thyroid:** RET Mutations/Fusions
*   **Cholangiocarcinoma:** IDH1 Mutations
*   **Glioma:** IDH1/2 Mutations (Vorasidenib)

---

## 4. QIAGEN
**Focus:** "therascreen" PCR kits, dominant in KRAS/EGFR/PIK3CA/FGFR.

### Device: therascreen KRAS RGQ PCR Kit
*   **NSCLC:** KRAS G12C (Sotorasib, Adagrasib)
*   **Colorectal:** KRAS G12C (Sotorasib + Panitumumab)
*   **Colorectal:** KRAS Wildtype confirmation (Cetuximab/Panitumumab)

### Device: therascreen PIK3CA RGQ PCR Kit
*   **Breast Cancer:** PIK3CA Mutations (Alpelisib, Capivasertib)

### Device: therascreen EGFR RGQ PCR Kit
*   **NSCLC:** EGFR Common Mutations (Afatinib, Gefitinib)

### Device: therascreen FGFR RGQ RT-PCR Kit
*   **Bladder Cancer:** FGFR3 Mutations (Erdafitinib)

---

## 5. Myriad Genetic Laboratories, Inc.
**Focus:** Homologous Recombination Deficiency (HRD) and BRCA.

### Device: BRACAnalysis CDx
*   **Ovarian Cancer:** BRCA1/2 (Olaparib, Rucaparib)
*   **Prostate Cancer:** BRCA1/2 (Olaparib)
*   **Breast Cancer:** BRCA1/2 (Olaparib)
*   **Pancreatic Cancer:** BRCA1/2 (Olaparib)

### Device: Myriad myChoice CDx
*   **Ovarian Cancer:** BRCA1/2 + Genomic Instability Score (HRD)
    *   **Drugs:** Olaparib + Bevacizumab, Niraparib

---

## 6. Guardant Health, Inc.
**Focus:** Liquid Biopsy leader alongside Foundation Medicine.

### Device: Guardant360 CDx
*   **NSCLC:**
    *   **Osimertinib:** EGFR Exon 19/L858R/T790M
    *   **Amivantamab:** EGFR Exon 20 Insertions
    *   **Sotorasib:** KRAS G12C
    *   **Trastuzumab Deruxtecan:** ERBB2 (HER2) Mutations
*   **Breast Cancer:** ESR1 Mutations (Elacestrant)

---

## 7. Other Notable Players

*   **Abbott Molecular:** FISH probes for **ALK** (NSCLC) and **HER2** (Breast). Also PCR for **IDH1/2** (AML).
*   **Agilent / Dako:** IHC/FISH kits for **PD-L1** (not gene level) and **HER2**.
*   **Caris Life Sciences:** "MI Cancer Seek" (NGS) approved for **BRAF** (Colorectal/Melanoma), **KRAS/NRAS** (Colorectal), and **PIK3CA** (Breast).
*   **Illumina:** "TruSight Oncology Comprehensive" (NGS kitted solution) approved for **NTRK** (Solid Tumors) and **RET** (NSCLC).
*   **Invivoscribe:** "LeukoStrat CDx" is the gold standard for **FLT3** mutation testing in **AML**.
*   **BioMÃ©rieux:** "THXID BRAF Kit" for **BRAF** in Melanoma.
